Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 13Esophageal Neoplasms 4Stomach Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2HER2-positive Breast Cancer 2Endometrial Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1

Interventions

atezolizumab 2tocilizumab 1spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1adagrasib 1Trastuzumab 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Docetaxel 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Trastuzumab × 30 days × Clear all
NCT03448042 2026-05-28

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Genentech, Inc.

Phase 1 Active not recruiting
123 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡